| Kindred At Home | |
| 320 North Cedar Bluff Rd, Suite 380, Knoxville, Tennessee 37923 | |
| (865) 584-3133 | |
| Name | Kindred At Home |
|---|---|
| Location | 320 North Cedar Bluff Rd, Suite 380, Knoxville, Tennessee |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services |
| Medicare ID | 447111 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 37705, 37710, 37716, 37721, 37722, 37725, 37738, 37760, 37764, 37771, 37772, 37774, 37779, 37806, 37807, 37813, 37814, 37821, 37822, 37830, 37843, 37849, 37860, 37862, 37863, 37865, 37866, 37871, 37876, 37877, 37890, 37909, 37912, 37914, 37917, 37918, 37919, 37920, 37921, 37922, 37923, 37924, 37931, 37932, 37934, 37938 |
| Quality Rating: |
News Archive
New research by scientists at the University of Chicago suggests a person's antibody response to influenza viruses is dramatically shaped by their pre-existing immunity, and that the quality of this response differs in individuals who are vaccinated or naturally infected.
RevenueMed, the global leader in healthcare business process outsourcing, today announced the launch of RevAbstract(TM) Services for EMR/EHR implementations.
NIH researchers have "identified two previously unknown steps in the spread of the malaria parasite in the bloodstream" and found a way to interfere with one stage of the process, which could lead to the development of new malaria drugs, United Press International reports (6/10). The study was published online in Current Biology, according to an NIH press release (6/10).
Janssen R&D Ireland announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver, which will take place April 24 to 28 in Amsterdam, The Netherlands.
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.
› Verified 7 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 99.8 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.5 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.2 | 99.6 |
| How often the home health team checked patients for depression | 97.6 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 86.1 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 89.3 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 98.9 | 96.4 |
News Archive
New research by scientists at the University of Chicago suggests a person's antibody response to influenza viruses is dramatically shaped by their pre-existing immunity, and that the quality of this response differs in individuals who are vaccinated or naturally infected.
RevenueMed, the global leader in healthcare business process outsourcing, today announced the launch of RevAbstract(TM) Services for EMR/EHR implementations.
NIH researchers have "identified two previously unknown steps in the spread of the malaria parasite in the bloodstream" and found a way to interfere with one stage of the process, which could lead to the development of new malaria drugs, United Press International reports (6/10). The study was published online in Current Biology, according to an NIH press release (6/10).
Janssen R&D Ireland announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver, which will take place April 24 to 28 in Amsterdam, The Netherlands.
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.
› Verified 7 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 89.2 | 79.6 |
| How often patients got better at getting in and out of bed | 90 | 81.1 |
| How often patients got better at bathing | 87.7 | 82.3 |
| How often patients’ breathing improved | 80.6 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 95.5 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 89.2 | 75 |
| How often home health patients had to be admitted to the hospital | 16 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 15.1 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 96.7 | 94 |
News Archive
New research by scientists at the University of Chicago suggests a person's antibody response to influenza viruses is dramatically shaped by their pre-existing immunity, and that the quality of this response differs in individuals who are vaccinated or naturally infected.
RevenueMed, the global leader in healthcare business process outsourcing, today announced the launch of RevAbstract(TM) Services for EMR/EHR implementations.
NIH researchers have "identified two previously unknown steps in the spread of the malaria parasite in the bloodstream" and found a way to interfere with one stage of the process, which could lead to the development of new malaria drugs, United Press International reports (6/10). The study was published online in Current Biology, according to an NIH press release (6/10).
Janssen R&D Ireland announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver, which will take place April 24 to 28 in Amsterdam, The Netherlands.
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.
› Verified 7 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
New research by scientists at the University of Chicago suggests a person's antibody response to influenza viruses is dramatically shaped by their pre-existing immunity, and that the quality of this response differs in individuals who are vaccinated or naturally infected.
RevenueMed, the global leader in healthcare business process outsourcing, today announced the launch of RevAbstract(TM) Services for EMR/EHR implementations.
NIH researchers have "identified two previously unknown steps in the spread of the malaria parasite in the bloodstream" and found a way to interfere with one stage of the process, which could lead to the development of new malaria drugs, United Press International reports (6/10). The study was published online in Current Biology, according to an NIH press release (6/10).
Janssen R&D Ireland announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver, which will take place April 24 to 28 in Amsterdam, The Netherlands.
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.
› Verified 7 days ago
The patient survey data of Kindred At Home is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 91 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 87 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 85 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 90 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 86 | 78 |
News Archive
New research by scientists at the University of Chicago suggests a person's antibody response to influenza viruses is dramatically shaped by their pre-existing immunity, and that the quality of this response differs in individuals who are vaccinated or naturally infected.
RevenueMed, the global leader in healthcare business process outsourcing, today announced the launch of RevAbstract(TM) Services for EMR/EHR implementations.
NIH researchers have "identified two previously unknown steps in the spread of the malaria parasite in the bloodstream" and found a way to interfere with one stage of the process, which could lead to the development of new malaria drugs, United Press International reports (6/10). The study was published online in Current Biology, according to an NIH press release (6/10).
Janssen R&D Ireland announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver, which will take place April 24 to 28 in Amsterdam, The Netherlands.
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.
› Verified 7 days ago
Kindred At Home Location: 320 North Cedar Bluff Rd, Suite 380, Knoxville, Tennessee 37923 Ratings: Phone: (865) 584-3133 | |
Nhc Homecare Knoxville Location: 9000 Executive Park Dr A205, Knoxville, Tennessee 37923 Ratings: Phone: (865) 539-0242 | |
Covenant Homecare Location: 3001 Lake Brook Blvd Suite 101, Knoxville, Tennessee 37909 Ratings: Phone: (865) 374-0600 | |
Camellia Home Health Location: 1700 Liberty Street, Knoxville, Tennessee 37921 Ratings: Phone: (865) 584-4010 | |
Tennova Healthcare Home Health Location: 1512 Coleman Road, Suite 310, Knoxville, Tennessee 37919 Ratings: Phone: (865) 647-3600 | |
University Of Tn Medical Center Home Care Services Location: 4435 Valley View Drive, Suite 101, Knoxville, Tennessee 37917 Ratings: Phone: (865) 544-6200 |